Index RUT
P/E -
EPS (ttm) -2.79
Insider Own 22.62%
Shs Outstand 59.24M
Perf Week -1.44%
Market Cap 144.87M
Forward P/E -
EPS next Y -2.22
Insider Trans 0.00%
Shs Float 54.69M
Perf Month -6.39%
Income -171.30M
PEG -
EPS next Q -0.52
Inst Own 71.85%
Short Float 15.73%
Perf Quarter -15.98%
Sales 0.00M
P/S -
EPS this Y 34.70%
Inst Trans -7.66%
Short Ratio 6.98
Perf Half Y -59.33%
Book/sh 3.97
P/B 0.52
EPS next Y -2.96%
ROA -52.07%
Short Interest 8.60M
Perf Year -93.23%
Cash/sh 3.39
P/C 0.61
EPS next 5Y -
ROE -56.29%
52W Range 1.79 - 30.20
Perf YTD -17.00%
Dividend Est. -
P/FCF -
EPS past 5Y -148.81%
ROI -58.85%
52W High -93.21%
Beta 0.37
Dividend TTM -
Quick Ratio 14.19
Sales past 5Y 0.00%
Gross Margin -
52W Low 14.53%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 14.19
EPS Y/Y TTM 0.34%
Oper. Margin 0.00%
RSI (14) 39.93
Volatility 5.05% 6.38%
Employees 80
Debt/Eq 0.04
Sales Y/Y TTM -
Profit Margin -
Recom 1.50
Target Price 12.17
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 50.21%
Payout -
Rel Volume 0.54
Prev Close 2.12
Sales Surprise -
EPS Surprise 22.25%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 1.23M
Price 2.05
SMA20 -8.56%
SMA50 -4.94%
SMA200 -42.63%
Trades
Volume 668,330
Change -3.30%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$7 → $16
Mar-12-24 Upgrade
Oppenheimer
Perform → Outperform
$12
Nov-07-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$77 → $8
Nov-07-23 Downgrade
Stifel
Buy → Hold
$6
Nov-07-23 Downgrade
Oppenheimer
Outperform → Perform
Nov-07-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$46 → $6
Nov-07-23 Downgrade
H.C. Wainwright
Buy → Neutral
Jun-14-23 Resumed
Credit Suisse
Outperform
$63
Mar-21-23 Initiated
Wells Fargo
Overweight
$77
Dec-19-22 Initiated
Goldman
Buy
$50
Nov-17-22 Initiated
Morgan Stanley
Overweight
$45
Sep-07-22 Initiated
Stifel
Buy
$45
Sep-01-22 Initiated
H.C. Wainwright
Buy
$36
May-09-22 Initiated
Credit Suisse
Outperform
$53
Mar-31-22 Initiated
Canaccord Genuity
Buy
$30
Feb-01-22 Initiated
Oppenheimer
Outperform
$30
Nov-15-21 Initiated
Piper Sandler
Overweight
$50
Nov-15-21 Initiated
Jefferies
Buy
$30
Show Previous Ratings
Sep-23-24 01:54PM
(Pharmaceutical Technology) +6.96%
08:00AM
Sep-06-24 08:00AM
Aug-30-24 08:00AM
07:04AM
08:00AM
Loading…
Aug-28-24 08:00AM
Aug-08-24 04:01PM
Jul-30-24 05:13PM
(Pharmaceutical Technology)
Jul-29-24 08:00AM
08:00AM
Jun-05-24 04:01PM
(GlobeNewswire) +6.77%
-37.78%
May-16-24 04:05PM
(GlobeNewswire) +18.85%
-5.02%
11:23AM
08:00AM
May-13-24 09:02PM
10:37AM
Loading…
10:37AM
May-09-24 08:59PM
04:01PM
May-02-24 04:05PM
Apr-30-24 12:00PM
Apr-17-24 08:45AM
05:45AM
Apr-15-24 01:15PM
Mar-27-24 06:20AM
Mar-20-24 05:45AM
Mar-18-24 06:02PM
Mar-11-24 07:29AM
07:00AM
Mar-07-24 08:52AM
08:00AM
08:00AM
Loading…
Mar-06-24 08:00AM
Mar-04-24 08:00AM
Feb-27-24 04:01PM
Feb-22-24 07:00AM
Feb-21-24 04:09PM
Feb-06-24 04:05PM
Dec-23-23 11:01AM
Nov-21-23 04:05PM
Nov-10-23 08:00AM
Nov-09-23 04:01PM
09:35AM
Nov-07-23 04:20PM
(Investor's Business Daily) -80.62%
08:47AM
07:00AM
Nov-06-23 04:01PM
Nov-04-23 12:16PM
Oct-11-23 11:37AM
Oct-10-23 04:18PM
12:55PM
07:44AM
(The Wall Street Journal)
Oct-09-23 04:01PM
Oct-07-23 05:00AM
Oct-04-23 11:01PM
Sep-29-23 12:43PM
Sep-08-23 05:07PM
Aug-30-23 04:05PM
Aug-15-23 07:23AM
Aug-10-23 04:01PM
Aug-03-23 04:05PM
Aug-02-23 04:06PM
Jul-12-23 07:22AM
Jul-03-23 02:09PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-31-23 08:00AM
May-12-23 08:57AM
(Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM
May-04-23 04:05PM
Mar-27-23 07:12AM
Mar-24-23 11:13AM
(Thomson Reuters StreetEvents) -5.23%
08:00AM
Mar-23-23 04:01PM
Mar-15-23 04:05PM
Mar-13-23 09:02AM
Mar-11-23 01:21PM
Feb-28-23 08:00AM
Feb-27-23 08:50AM
Feb-13-23 09:55AM
Feb-10-23 08:50AM
Feb-03-23 12:00PM
Jan-26-23 09:55AM
08:00AM
Jan-25-23 08:50AM
Jan-12-23 08:00AM
Jan-05-23 08:00AM
Jan-04-23 09:55AM
Dec-27-22 07:11AM
Dec-22-22 07:26AM
Dec-01-22 04:05PM
Nov-22-22 08:00AM
Nov-11-22 06:35PM
Nov-03-22 04:01PM
Oct-27-22 04:05PM
09:00AM
Oct-24-22 09:55AM
Sep-19-22 09:31AM
08:00AM
Sep-16-22 07:16PM
Sep-14-22 02:01PM
Aug-29-22 04:05PM
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mohan Raju CEO AND PRESIDENT Jun 10 '24 Option Exercise 0.20 96,778 19,356 1,675,028 Jun 11 04:47 PM Krueger Christopher W CHIEF BUSINESS OFFICER Apr 02 '24 Sale 5.40 1,651 8,921 284,999 Apr 03 07:37 PM Nuss John CHIEF SCIENTIFIC OFFICER Apr 02 '24 Sale 5.40 1,651 8,921 264,998 Apr 03 07:33 PM Mohan Raju CEO AND PRESIDENT Apr 02 '24 Sale 5.40 4,312 23,299 1,578,250 Apr 03 07:32 PM Auster Martin CHIEF FINANCIAL OFFICER Apr 02 '24 Sale 5.40 1,405 7,592 24,303 Apr 03 07:30 PM Krueger Christopher W CHIEF BUSINESS OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 286,650 Mar 29 06:15 PM Auster Martin CHIEF FINANCIAL OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 25,708 Mar 29 06:12 PM Mohan Raju CEO AND PRESIDENT Mar 28 '24 Option Exercise 0.00 11,843 0 1,582,562 Mar 29 06:09 PM Nuss John CHIEF SCIENTIFIC OFFICER Mar 28 '24 Option Exercise 0.00 4,531 0 266,649 Mar 29 06:07 PM Nuss John Chief Scientific Officer Dec 20 '23 Sale 2.12 17,628 37,334 262,118 Dec 21 08:14 PM Krueger Christopher W Chief Business Officer Dec 20 '23 Sale 2.12 5,293 11,210 282,119 Dec 21 08:12 PM Mohan Raju CEO and President Dec 20 '23 Sale 2.12 58,860 124,660 1,570,719 Dec 21 08:10 PM Mohan Raju CEO and President Dec 17 '23 Option Exercise 0.00 116,668 0 1,629,579 Dec 19 05:30 PM Nuss John Chief Scientific Officer Dec 17 '23 Option Exercise 0.00 34,931 0 279,746 Dec 19 05:27 PM Krueger Christopher W Chief Business Officer Dec 17 '23 Option Exercise 0.00 10,479 0 287,412 Dec 19 05:25 PM NSV Partners III LP 10% Owner Oct 09 '23 Sale 30.03 49,152 1,475,858 8,439,635 Oct 11 04:21 PM Subramaniam Somu Director Oct 09 '23 Sale 30.03 49,152 1,475,858 8,439,635 Oct 11 04:18 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite